Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2-advanced breast cancer (aBC): Combined biomarker analyses from a phase 1/2 study in postmenopausal women and a phase 1 study in postmenopausal Japanese women Meeting Abstract
| Authors: | Iwata, H.; Bardia, A.; Lord, S.; Linden, H. M.; Campone, M.; Tamura, K.; Yonemori, K.; Mukohara, T.; Combeau, C.; Ternes, N.; Carene, D.; Ming, J.; Lee, J. S.; Celanovic, M.; Bauchet, A. L.; Bouaboula, M.; Tanaka, T.; Kawabata, Y.; Chandarlapaty, S. |
| Abstract Title: | Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2-advanced breast cancer (aBC): Combined biomarker analyses from a phase 1/2 study in postmenopausal women and a phase 1 study in postmenopausal Japanese women |
| Meeting Title: | 113th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 82 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2022 Apr 8-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-06-15 |
| Language: | English |
| ACCESSION: | WOS:000892509500035 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2022-CT517 |
| Notes: | Meeting Abstract: CT517 -- Source: Wos |
